Clinical Trials
2 trialsNCT05528458 2026-04-28
Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Samsung Medical Center
Phase 2 Recruiting
NCT02759835 2024-06-07
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
National Institutes of Health Clinical Center (CC)
Phase 2 Completed